BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Pharm Country

  Aclaris Therapeutics Announces the Allowance of a U.S. Patent Application and Issuance of a Japanese Patent Covering Tofacitinib for Treating Hair Loss Disorders

  This U.S. application will become the latest patent to issue in Aclaris’ JAK inhibitor drug development program for hair loss disorders.

  October 24, 2017

   · 

  5 min read
• Business

  Biogen Reports Quarterly Revenues of $3.1 Billion

  Biogen Inc. today reported third quarter 2017 financial results, including: Total revenues of $3.1 billion, a 4% increase versus the prior year or a 13% increase excluding hemophilia revenues*.

  October 24, 2017

   · 

  25 min read
• Biotech Beach

  MabVax Therapeutics Expands Intellectual Property Estate by Filing a New Patent Application on its Fully-Human Antibody Discoveries

  MabVax Therapeutics announced that the Company has filed a patent application for its series of HuMab-Tn fully-human monoclonal antibodies that target the tumor associated Thomsen-nouveau antigen that will be developed as therapeutic and diagnostic products targeting ovarian, lung and breast cancers.

  October 24, 2017

   · 

  5 min read
• Biotech Beach

  Neural Analytics Receives $10 Million Contract From the United States Army to Develop Portable Point of Injury Device to Assess Combat-Related Traumatic Brain Injury

  Neural Analytics today announced that the Department of Defense (DoD) has awarded the company a $10 million contract to develop and supply a portable, point of injury device for assessing combat-related traumatic brain injury (TBI).

  October 24, 2017

   · 

  3 min read
• Genetown

  Sage Therapeutics to Report Third Quarter 2017 Financial Results on Thursday, November 2, 2017

  Sage Therapeutics today announced that the company will host a conference call and live webcast on Thursday, November 2, 2017 at 8:00 am ET to report its third quarter 2017 financial results and to discuss recent business updates.

  October 24, 2017

   · 

  1 min read
• Business

  Sites Medical Licenses its OsteoSync Ti Technology to Integrity Implants for Incorporation into their FlareHawk Family of Expandable Implants

  Sites Medical announced it has entered into a licensing agreement with Integrity Implants, to incorporate its proprietary OsteoSync Ti technology into Integrity’s novel multi-dimensional expandable interbody devices.

  October 24, 2017

   · 

  3 min read
• Arch Biopartners Closes Convertible Note Financing

  Arch Biopartners Inc. announced it has closed a non-brokered, unsecured convertible note financing for gross proceeds of CAD $500,000 on October 23, 2017.

  October 24, 2017

   · 

  3 min read
• Business

  Bigfoot Biomedical and Ypsomed Announce Agreement

  Bigfoot Biomedical and Ypsomed announced that the companies have entered into an agreement under which Ypsomed will supply Bigfoot with a customized proprietary version of its Orbit infusion sets as part of Bigfoot’s investigational automated insulin pump-based solution for use in a pivotal trial.

  October 24, 2017

   · 

  3 min read
• Policy

  Prevtec Microbia Receives Market Authorization for Coliprotec F4/F18 in Russia and CIS countries

  Prevtec Microbia Inc. is pleased to announce that a Market Authorization was received for Russia, including all CIS countries, for its bivalent vaccine Coliprotec F4/F18, a front line product against post weaning diarrhea (PWD) in pigs caused by E.coli.

  October 24, 2017

   · 

  2 min read
• 

  Drug Development

  Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients With MRSA Infections and Challenging Comorbidities

  The phase III data was published in the Journal of Antimicrobial Chemotherapy.

  October 24, 2017

   · 

  6 min read